Literature DB >> 12932724

An investigation into the structure and bioavailability of alpha-tocopherol dispersions in Gelucire 44/14.

S A Barker1, S P Yap, K H Yuen, C P McCoy, J R Murphy, D Q M Craig.   

Abstract

In this investigation we describe the preparation, physical characterisation and in vivo behaviour of solid dispersions of a liquid nutraceutical, alpha-tocopherol, in Gelucire 44/14 with a view to establishing whether dispersion in this matrix may provide a means of formulating a liquid drug in a solid dosage form while also improving the oral bioavailability. Using Vitamin E Preparation USP as the source of alpha-tocopherol, dispersions were prepared using a melt-fusion method with active loadings up to 50% (w/w) and characterised using differential scanning calorimetry and optical microscopy. Capsules containing 300 IU alpha-tocopherol were manufactured and the absorption profiles compared to a commercial soft gelatin capsule preparation in healthy human volunteers. Confocal laser scanning microscopy (CLSM) studies were performed in order to elucidate the mechanism by which drug release may be occurring. Differential scanning calorimetry studies indicated that the presence of the active had a negligible effect on the melting profile of the carrier, indicating limited miscibility between the two components, a conclusion supported by the microscopy studies. Similarly, the dispersions were shown to exhibit a glass transition corresponding to the incorporated drug, indicating molecular cooperativity and hence phase separation from the lipid base. Despite the phase separation, it was noted that capsules stored for 18 months under ambient conditions showed no evidence of leakage. Bioavailability studies in six healthy male volunteers indicated that the Gelucire 44/14 formulation showed an approximately two-fold increase in total alpha-tocopherol absorption compared to the commercial preparation. Confocal laser scanning microscopy studies indicated that, on contact with water, the dispersions formed two interfacial layers, from which the Gelucire 44/14 disperses in the liquid medium as small particles. Furthermore, evidence was obtained for the dispersed material becoming incorporated into the hydrated lipid. In conclusion, the dispersion of the liquid drug in Gelucire 44/14 appears to allow the dual advantages of the preparation of a solid formulation and improved bioavailability of this material.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932724     DOI: 10.1016/s0168-3659(03)00261-x

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

1.  Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine.

Authors:  Amit A Kale; Vandana B Patravale
Journal:  AAPS PharmSciTech       Date:  2008-02-05       Impact factor: 3.246

2.  Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation.

Authors:  Shyam Shimpi; Bhaskar Chauhan; K R Mahadik; Anant Paradkar
Journal:  AAPS PharmSciTech       Date:  2004-07-12       Impact factor: 3.246

3.  Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir.

Authors:  Shilpi Sinha; Mushir Ali; Sanjula Baboota; Alka Ahuja; Anil Kumar; Javed Ali
Journal:  AAPS PharmSciTech       Date:  2010-03-18       Impact factor: 3.246

4.  Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA): formulation design and optimization studies.

Authors:  Yu-Tsai Yang; Anthony J Di Pasqua; Yong Zhang; Katsuhiko Sueda; Michael Jay
Journal:  Pharm Dev Technol       Date:  2013-09-19       Impact factor: 3.133

5.  Development of Gelucire 43/01 beads of metformin hydrochloride for floating delivery.

Authors:  Sunil K Jain; Anuj Gupta
Journal:  AAPS PharmSciTech       Date:  2009-10-15       Impact factor: 3.246

6.  In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14.

Authors:  Sylvie Fernandez; Stéphanie Chevrier; Nicolas Ritter; Bruno Mahler; Frédéric Demarne; Frédéric Carrière; Vincent Jannin
Journal:  Pharm Res       Date:  2009-05-19       Impact factor: 4.200

7.  Clinical studies with oral lipid based formulations of poorly soluble compounds.

Authors:  Dimitrios G Fatouros; Ditte M Karpf; Flemming S Nielsen; Anette Mullertz
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

8.  Floating granules of ranitidine hydrochloride-gelucire 43/01: formulation optimization using factorial design.

Authors:  Dasharath M Patel; Natavarlal M Patel; Viral F Patel; Darshini A Bhatt
Journal:  AAPS PharmSciTech       Date:  2007-04-13       Impact factor: 3.246

9.  Extended release felodipine self-nanoemulsifying system.

Authors:  Pradeep R Patil; Shailesh V Biradar; Anant R Paradkar
Journal:  AAPS PharmSciTech       Date:  2009-05-05       Impact factor: 3.246

10.  Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study.

Authors:  Basmah N Aldosari; Alanood S Almurshedi; Iman M Alfagih; Bushra T AlQuadeib; Mohammad A Altamimi; Syed Sarim Imam; Afzal Hussain; Faleh Alqahtani; Ehab Elzayat; Sultan Alshehri
Journal:  AAPS PharmSciTech       Date:  2021-05-24       Impact factor: 4.026

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.